Jason Loveridge
Chief Executive Officer presso 4SC AG
Posizioni attive di Jason Loveridge
Società | Posizione | Inizio | Fine |
---|---|---|---|
4SC AG | Chief Executive Officer | 21/09/2016 | - |
Warambi Ltd. | Corporate Officer/Principal | - | - |
Corticrine Ltd.
Corticrine Ltd. Pharmaceuticals: MajorHealth Technology Part of Actinogen Medical Ltd., Corticrine Ltd. develops and manufactures drugs. The private company is based in Edinburgh, UK. Corticrine was acquired by Actinogen Medical Ltd. on December 01, 2014 for $4.97 million. | Director/Board Member | - | - |
Invex Therapeutics Ltd. (United Kingdom) | Director/Board Member | - | - |
Storia della carriera di Jason Loveridge
Precedenti posizioni note di Jason Loveridge
Società | Posizione | Inizio | Fine |
---|---|---|---|
INVEX THERAPEUTICS LTD | Chairman | 08/03/2019 | 10/07/2023 |
Founder | 08/03/2019 | 10/07/2023 | |
Warambi SARL | Director/Board Member | 01/01/2005 | 01/01/2020 |
Corporate Officer/Principal | 01/01/2005 | 01/01/2020 | |
JDS BioPharma Pty Ltd. | Director/Board Member | 01/01/2006 | 01/01/2020 |
ACTINOGEN MEDICAL LIMITED | Director/Board Member | 01/12/2014 | 28/11/2018 |
Chairman | 30/11/2016 | 01/03/2017 | |
RESONANCE HEALTH LIMITED | Director/Board Member | 07/02/2013 | 30/06/2017 |
Independent Dir/Board Member | 07/02/2013 | 30/06/2017 | |
░░░░░ ░░░░░░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░ ░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░ ░░░░░ ░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Jason Loveridge
University of Adelaide | Doctorate Degree |
The University of New South Wales | Undergraduate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 7 |
Australia | 7 |
Francia | 5 |
Posizioni
Director/Board Member | 11 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 3 |
Settori
Health Technology | 10 |
Finance | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 5 |
---|---|
4SC AG | Health Technology |
RESONANCE HEALTH LIMITED | Health Services |
BIOFRONTERA AG | Health Technology |
ACTINOGEN MEDICAL LIMITED | Health Technology |
INVEX THERAPEUTICS LTD | Health Technology |
Aziende private | 13 |
---|---|
Arthro Kinetics Ltd.
Arthro Kinetics Ltd. Medical SpecialtiesHealth Technology Arthro Kinetics develops manufactures and markets advanced biological implants for joint regeneration and surgical instrument and access systems for endoscopic spine surgery. The Company aims to develop a portfolio of biological implants for insertion by endoscopic spine surgery techniques, thereby setting new standards of surgical care. The Company has developed and is marketing CaReS, its first biological cartilage repair product, and K.I.S.S., its comprehensive spinal surgical instruments system for endoscopic spinal access and surgical intervention. | Health Technology |
IT Asset Management SA
IT Asset Management SA Investment ManagersFinance IT Asset Management SA (ITAM), established in 1994, is an independent asset management firm based in Paris, France. ITAM is wholly-owned by their management and employees. The firm provides financial advisory services and manages discretionary portfolios and mutual funds (FCPs and a compartment of a Luxembourg-based SICAV) for institutional clients and private individuals. | Finance |
BioPharma Capital Ltd. | Finance |
Korda & Co. | Finance |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Health Technology |
Anaconda Pharma SASU
Anaconda Pharma SASU BiotechnologyHealth Technology Anaconda Pharma SAS provides biotechnology services. It offers biotechnology services and develops treatments against infections by human papillomavirus. The company was founded in 2003 and is headquartered in Villejuif, France. | Health Technology |
Parvulus Suisse SA
Parvulus Suisse SA Medical SpecialtiesHealth Technology Parvulus Suisse SA provides medical technology. It focused on commercializing devices for cardiac surgery distribution, manufacturing, sales and distribution. The company was founded in March 20011 and is headquartered in Lonay, Switzerland. | Health Technology |
Warambi SARL | |
JDS BioPharma Pty Ltd. | |
Parvulus Medical SAS | Distribution Services |
Corticrine Ltd.
Corticrine Ltd. Pharmaceuticals: MajorHealth Technology Part of Actinogen Medical Ltd., Corticrine Ltd. develops and manufactures drugs. The private company is based in Edinburgh, UK. Corticrine was acquired by Actinogen Medical Ltd. on December 01, 2014 for $4.97 million. | Health Technology |
Warambi Ltd. | |
Invex Therapeutics Ltd. (United Kingdom) |
- Borsa valori
- Insiders
- Jason Loveridge
- Esperienza